More recently, WT1 has been suggested as a critical biomarker for AML, not only due to its high expression in leukemic cells but also because of the relationship between WT1 expression and recurrent cytogenetic mutations which are known to drive AML pathogenesis [10,11]. Here, WT1 is linked to acute myeloid leukemia.